Fifty 1 Labs (OTC: FITY) announced that its subsidiary, Fifty 1 AI Labs, has entered into a partnership with LUNR Aerospace to develop AI-driven drug repurposing initiatives for space medicine. The collaboration will address key health challenges in microgravity, including immune support, musculoskeletal resilience, neuro-ocular protection, cardiovascular stability, cognitive performance, sleep optimization and metabolic longevity.
Pilot programs will test AI-curated therapeutics and nutraceuticals in space-relevant conditions, offering a cost-efficient path to innovation. With the global space medicine market projected to grow from USD 948.7 million in 2025 to USD 1.97 billion by 2032 at an 11% CAGR, the partnership positions Fifty 1 Labs to capitalize on expanding demand while creating dual-use opportunities across aerospace, defense, longevity and precision health markets.
The partnership represents a significant advancement in addressing the unique medical challenges faced by astronauts during space missions. Microgravity environments present numerous health risks that require innovative solutions, and AI-driven drug repurposing offers a practical approach to developing treatments more efficiently than traditional drug discovery methods.
For more information about Fifty 1 AI Labs and their AI-driven drug discovery approach, visit https://fifty1labs.com/. The company specializes in using artificial intelligence to unlock new potential in proven medicines by repurposing safe, off-patent compounds to accelerate smarter therapies that improve lives and reduce costs.
This collaboration comes at a critical time as space exploration and commercial space travel continue to expand, creating increased demand for effective medical solutions that can protect astronaut health during extended missions. The development of space medicine technologies also has significant implications for terrestrial healthcare, as many of the solutions developed for space environments can be adapted for use on Earth.
